EU clears peanut allergy treatment for Aimmune Palforzia
Palforzia from Aimmune Therapeutics has received approval from the European Commission (EC) for the treatment of a peanut allergy. The EC has approved Palforzia for use in children aged 4 to 17 years with a confirmed diagnosis of peanut…